Webthe PORTEC-1 trial of 8% and 14%, respectively.9 These conclu-sions were confirmed in analysis of long-term outcomes.10 Based on these results it might be questioned if there is still an indication for adjuvant treatment in stage I endometrial cancer. However, in both the PORTEC-1 and Gynaecologic Oncology Group (GOG)−99 Webthe PORTEC Study Group* Summary Background The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer. We updated the analysis to investigate patterns of recurrence and did a post-hoc survival analysis.
Login to your account - The Lancet Oncology
WebPORTEC-3, CKTO 2006-04, CME P06.031, version 28 January 2009 5 1. STUDY SYNOPSIS Title Randomised Phase III Trial Comparing Concurrent Chemoradiation and WebMar 19, 2024 · In a comprehensive analysis of the PORTEC-1 and-2 biobank an integrated clinicopathological and molecular risk profile was determined which separated the current … reddit investing intu
Drug Trial Snapshot: EMPAVELI FDA
WebFeb 12, 2024 · The PORTEC-3 investigators randomly assigned patients with high-risk endometrial cancer to pelvic radiotherapy alone or adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy), a regimen based on the phase 2 RTOG-9708 trial. 5-year failure-free survival favoured the chemoradiotherapy group with a 7% difference between … WebApr 10, 2024 · PORTEC-2 is a randomized trial comparing two forms of adjuvant radiation therapy in women with so-called high-intermediate-risk carcinomas of the endometrium. The investigators tested the ... WebThe PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT) for women with stage I-III endometrial cancer with high-risk features (HREC). Since the TCGA defined 4 molecular subgroups of EC with strong prognostic value, we investigated outcomes and impact of chemotherapy ... reddit investing qqq